prikaz prve stranice dokumenta Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
  Download
PDF 370.07 KB
Scientific paper - Original scientific paper
Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
Medical Hypotheses, 144 (2020); 109903. https://doi.org/10.1016/j.mehy.2020.109903
Bašić-Jukić, Nikolina

Cite this document

Bašić Jukić, N. (2020). Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?. Medical Hypotheses, 144.. doi: 10.1016/j.mehy.2020.109903

Bašić Jukić, Nikolina. "Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?." Medical Hypotheses, vol. 144, 2020. https://doi.org/10.1016/j.mehy.2020.109903

Bašić Jukić, Nikolina. "Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?." Medical Hypotheses 144 (2020). https://doi.org/10.1016/j.mehy.2020.109903

Bašić Jukić, N. (2020) 'Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?', Medical Hypotheses, 144. doi: 10.1016/j.mehy.2020.109903

Bašić Jukić N. Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?. Medical Hypotheses [Internet]. 2020 November [cited 2024 April 12];144. doi: 10.1016/j.mehy.2020.109903

N. Bašić Jukić, "Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?", Medical Hypotheses, vol. 144, November 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:452849. [Accessed: 12 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
AuthorNikolina Bašić-Jukić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Information on treatment of COVID-19 infection in renal transplant recipients is scarce, especially in symptomatic patients and patients with recent major clinical events. This group of patients suffers from different opportunistic infections which may coexist with COVID-19. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Besides the immunosuppression reduction which is supposed to be beneficial, immunoglobulins with their immunomodulatory effects and possible antiviral role, may increase a possibility for favorable outcome.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedical Hypotheses
Numberingvol. 144, 109903
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2020.109903
URN:NBNurn:nbn:hr:105:452849
Publication2020-11
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S030698772030949X
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2021-03-30 09:49:24